We have acted as counsel to NextNRG, Inc., a Delaware corporation (the “Company”), in connection with the offer and sale by the Company of up to 5,494,770 shares (the “Shares”) of its common stock, par value $0.0001 per share, pursuant to that certain securities purchase agreement, dated as of September 8, 2025 by and between the Company and an accredited investor (the “Purchase Agreement”), consisting of: (i) up to 1,747,631 Shares issuable by the Company upon conversion of senior secured convertible notes (the “Notes”), in an aggregate principal amount of $2,950,000, issued by the Company on November 12, 2025 (the “Third Closing”), (ii) up to 750,000 Shares issuable upon exercise of warrants (the “Warrants”) to purchase up to 750,000 Shares, issued by the Company at the Third Closing, (iii) up to 174,764 Shares issuable by the Company upon conversion of due diligence notes (the “Due Diligence Notes”), in an aggregate principal amount of $295,000 of Due Diligence Notes, issued by the Company at the Third Closing, (iv) up to 75,000 Shares issuable upon exercise of due diligence warrants (the “Due Diligence Warrants”) to purchase up to 75,000 Shares, issued by the Company at the Third Closing, and (v) up to 2,747,385 Shares issuable by the Company upon conversion of additional Notes and additional Due Diligence Notes or the exercise of additional Warrants and additional Due Diligence Warrants that the Company may issue in any additional closing, if any, pursuant to the Purchase Agreement.

The Shares will be offered and sold pursuant to the prospectus supplement, dated September 9, 2025, as amended on November 18, 2025 (the “Prospectus Supplement”), supplementing the prospectus (the “Base Prospectus”) that forms part of the Company’s shelf registration statement on Form S-3, as amended (File No. 333-268960) (the “Registration Statement”). As used in this opinion letter, the term “Prospectus” means the Prospectus Supplement and the Base Prospectus, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”). The Purchase Agreement, the Notes, the Warrants, the Due Diligence Notes and the Due Diligence warrants were filed with the Securities and Exchange Commission (the “Commission”) as Exhibits 10.1, 10.2, 10.3. 10.4 and 10.5 to the Company’s Current Report on Form 8-K, dated September 9, 2025

1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036 T (212) 930-9700 | F (212)

930-9725 | WWW.SRFC.LAW

We have examined originals or copies, certified or otherwise identified to our satisfaction, of such corporate records of the Company and other certificates and documents of officials of the Company, public officials and others as we have deemed appropriate for purposes of this letter. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies.

Based upon the foregoing and subject to the assumptions, exceptions, qualifications and limitations set forth hereinafter, we are of the opinion that the Shares have been duly authorized for issuance and, when issued in accordance with the terms and conditions of the Purchase Agreement, the Notes, the Warrants, the Due Diligence Notes and the Due Diligence warrants, and upon the receipt by the Company of any applicable exercise price therefore, will be validly issued, fully paid and nonassessable.

In rendering the foregoing opinion, we have assumed that: (i) the Company will issue and deliver the Shares in the manner contemplated by the Registration Statement, the Prospectus, the Purchase Agreement, the Notes, the Warrants, the Due Diligence Notes and the Due Diligence Warrants; and (ii) the Shares will be issued in compliance with applicable federal and state securities laws.

The opinions we express herein are limited to matters involving the Delaware General Corporation Law.

This opinion has been prepared solely for use in connection with the filing of the Prospectus Supplement on the date of this letter and may be relied upon for no other purpose without our prior written consent.

We hereby consent to the filing of this letter with the Commission as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issuance and sale of the Shares in accordance with the requirements of Item 601(b)(5) of Regulation S−K under the Securities Act and to the reference to our firm therein and in the Prospectus under the caption “Legal Matters.” In giving such consent, we do not thereby admit that this firm is within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission under such Section.